Article
Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 1 Sept 2018
Chen C-H, Hung C-H, Wang J-H, Lu S-N, Hu T-H, Lee C-M
Abstract excerpt
OBJECTIVE: To investigate the long-term incidence and predictors for hepatitis B surface antigen (HBsAg) loss after nucleoside analogue therapy. METHODS: The study included 411 noncirrhotic chronic hepatitis B patients (148 hepatitis B e antigen (HBeAg)-positive and 263 HBeAg-negative patients) who were treated with lamivudine (n = 110) or entecavir (n = 301) with posttreatment follow-up of at least 12 months....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.